- cytokines,

a2

- anthracyclines including daunomycin and dauxorubicin,

- vinca-alkaloids, including vinblastine and vincristine,

- paclitaxel (or Taxol, DCI).--

R E M A R K S

The above changes in the specification and claims merely place this national stage application in the same condition as it was during Chapter II of the international stage, with the multiple dependencies being removed.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

Respectfully submitted,

YOUNG & THOMPSON

By _____

Andrew J. Patch
Attorney for Applicants
Registration No. 32,925
Customer No. 00466
745 South 23rd Street
Arlington, VA 22202
Telephone: 703/521-2297

May 25, 2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Amend claim 3 as follows:

--3. (amended) The use according to claim 1~~ or claim 2~~, of compounds inhibiting the activation of MF-κB connected specifically to the transmembranal receptors of the cytokins of class I in the cells of the organism, such as compounds selected from growth hormone or erythropoietin.--

Amend claim 4 as follows:

--4. (amended) The use according to ~~one of~~ claim~~s~~ 1~~ to 3~~:

- of the human growth hormone, as obtained by extraction from hypophysary extracts, and purification,

- or of the recombinant human growth hormone as encoded by the nucleotide sequence SEQ ID NO 1, or by any nucleotide sequence derived from this latter by degeneracy of the genetic code and being nevertheless capable of encoding for the human growth hormone whose sequence in amino acids is represented by SEQ ID NO 2, said growth hormone being obtained by transformation of appropriate cells with the help of vectors containing a nucleotide sequence as described, recovery of the recombinant protein produced by said cells, and purification,

- or of any peptide sequence derived by addition and/or deletion and/or substitution of one or several amino acids of the sequence SEQ ID NO 2,

and preserving the property of human growth hormone of inhibiting the activation of NF-κB.--

Amend claim 5 as follows:

--5. (amended) The use according to ~~one of~~ claim~~s~~ 1~~ to 3~~:

- of recombinant human erythropoietin such as encoded by the nucleotide sequence SEQ ID NO 3, or by any nucleotide sequence derived from this latter by degeneracy of the genetic code and being nevertheless capable of encoding for human erythropoietin whose sequence in amino acids is represented by SEQ ID NO 4, said erythropoietin being obtained by transformation of appropriate cells with the help of vectors contained in a nucleotide sequence as described above, recovery of the recombinant protein produced by said cells, and purification,

- or any peptide sequence derived by addition and/or deletion and/or substitution of one or several amino acids of the sequence SEQ ID NO 4, and preserving the property of inhibiting the activation of NF-κB.--

Amend claim 6 as follows:

--6. (amended) The use compounds inhibiting the activation of NF-κB according to ~~one of~~ claim~~s~~ 1~~ to 7~~, in combination with one or several cytotoxic molecules adapted to activate the NF-κB factor, selected from:

- cytokines,
- anthracyclines, including daunomycin, and dauxorubicin,
- vinca-alkaloids, such as vinblastine and vincristine,
- paclitaxel (or Taxel, DCI).--

Amend claim 7 as follows:

--7. (amended) The use of compounds inhibiting the activation of NF-κB according to ~~one of~~ claim~~s~~ 1~~ 6~~, characterized in that the dosage of the cytotoxic molecules used in combination with said compounds is about

2 to about 5 times less than the dosage of these same molecules used alone in the scope of treatment of malignant hemopathies and solid tumors.--

--10. (amended) Product according to claim 8~~ or 9~~, characterized in that it comprises:

- human growth hormone, such as obtained by the extraction from hypophysary extracts, and purification,

- or recombinant human growth hormone as encoded by the nucleotide sequence SEQ ID NO 1, or by any nucleotide sequence derived from this latter by degeneracy of the genetic code and being nevertheless capable of encoding for human growth hormone whose amino acid sequence is represented by SEQ ID NO 2, said growth hormone being obtained by a transformation of suitable cells with the help of vectors containing a nucleotide sequence such as described above, recovery of the recombinant protein produced by said cells, and purification,

- or any peptide sequence derived by addition and/or deletion and/or substitution of one or several amino acids of the sequence SEQ ID NO 2, and keeping the property of the human growth hormone of inhibiting the activation of NF-κB.--

Amend claim 11 as follows:

--11. (amended) Product according to claim 8~~ or 9~~, characterized in that it comprises:

- recombinant human erythropoietin as encoded by the nucleotide sequence SEQ ID NO 3, or by any nucleotide sequence derived from this latter by degeneracy of the genetic code and being nevertheless capable of encoding for human erythropoietin whose sequence in amino acids is

represented by SEQ ID NO 4, said erythropoietin being obtained by transformation of suitable cells with the help of vectors containing a nucleotide sequence as described above, recovery of the recombinant protein produced by said cells, and purification,

- or any peptide sequence derived by addition and/or deletion and/or substitution of one or several amino acids of the sequence SEQ ID NO 4, and keeping the property of human erythropoietin of inhibiting the activation of NF-κB.--

Amend claim 12 as follows:

--12. (amended) Product according to ~~one of~~ claim~~s~~ 8~~ to 11~~, characterized in that it comprises as cytotoxic molecule susceptible of activating the NF-κB factor, any molecule selected from the following:

- cytokines,
- anthracyclines including daunomycin and dauxorubicin,
- vinca-alkaloids, including vinblastine and vincristine,
- paclitaxel (or Taxol, DCI).--